Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab

Phase 2ForalumabPositive

AI Analysis

Summary

Tiziana announced that the last patient has completed the final visit in the Phase 2a INFORM-MS trial evaluating intranasal foralumab for multiple sclerosis. Trial completion opens the pathway for data analysis and future development.

Clinical Trial Data

Phase

Outcome Details

Last patient completed last visit in Phase 2a trial

Importance:5/10

Sentiment:

0.30

Phase 2Multiple SclerosisIntranasalTrial Completion

Related Companies

$TLSA

Read the original article

Published by yahoo_finance on September 21, 2026 11:00 AM

Read Original